Payment overview · 2025
General Payments
$1,094.61
27 reported records · 6 companies
Healthcare provider profile · identity verified
John Dudley Weaver, MD
Allopathic & Osteopathic Physicians|Family Medicine · JOHNSON CITY, TX · NPI 1841248408
Verified facts
What the public records show
CMS Open Payments records show John Dudley Weaver, MD received $1,094.61 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $530.24 | 48.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $182.01 | 16.6% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $170.17 | 15.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.00 | 14.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.42 | 4.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.77 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,094.61 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $289.12 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $284.70 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $284.70 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $170.17 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $131.12 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.43 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.42 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $6.13 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $5.58 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 90 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 384 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 317 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 309 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 281 | 72 |
| Losartan Potassium | Losartan Potassium | 220 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 214 | 52 |
| Gabapentin | Gabapentin | 169 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 166 | 32 |
| Allopurinol | Allopurinol | 150 | 33 |
| Metformin Hcl | Metformin Hcl | 135 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 27 |
| Potassium Chloride | Potassium Chloride | 111 | 19 |
| Furosemide | Furosemide | 101 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 17 |
| Simvastatin | Simvastatin | 94 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 17 |
| Eliquis | Apixaban | 90 | 13 |
| Omeprazole | Omeprazole | 90 | 25 |
| Ozempic | Semaglutide | 88 | 12 |
| Sertraline Hcl | Sertraline Hcl | 88 | 21 |
| Trazodone Hcl | Trazodone Hcl | 87 | 18 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 81 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 21 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 79 | 63 |
| Farxiga | Dapagliflozin Propanediol | 78 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 19 |
| Xarelto | Rivaroxaban | 69 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 27 |
| Carvedilol | Carvedilol | 64 | 21 |
| Famotidine | Famotidine | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 55 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 15 |
| Prednisone | Prednisone | 51 | 34 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | suppressed |
| Spironolactone | Spironolactone | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | 15 |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 41 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 11 |
| Propranolol Hcl | Propranolol Hcl | 36 | 11 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Finasteride | Finasteride | 31 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 22 |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Ramipril | Ramipril | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 18 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | 13 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Rybelsus | Semaglutide | 15 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,094.61 · 27 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, NURTEC ODT, Ozempic, Rybelsus, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error